Barclays Forecasts Strong Price Appreciation for Icon (NASDAQ:ICLR) Stock

Icon (NASDAQ:ICLR) had its price objective lifted by research analysts at Barclays from $120.00 to $150.00 in a note issued to investors on Friday,Benzinga reports. The brokerage presently has an “equal weight” rating on the medical research company’s stock. Barclays‘s target price points to a potential upside of 11.55% from the company’s current price.

Other equities research analysts have also recently issued reports about the company. TD Cowen raised Icon from a “hold” rating to a “buy” rating and dropped their price objective for the company from $183.00 to $120.00 in a research report on Wednesday, February 18th. Zacks Research lowered Icon from a “hold” rating to a “strong sell” rating in a research report on Wednesday, February 25th. Royal Bank Of Canada restated a “sector perform” rating and set a $126.00 target price on shares of Icon in a research note on Friday. Rothschild & Co Redburn set a $100.00 price target on shares of Icon and gave the stock a “neutral” rating in a research note on Tuesday, February 17th. Finally, Bank of America reissued an “underperform” rating and set a $105.00 price objective on shares of Icon in a report on Wednesday. Seven equities research analysts have rated the stock with a Buy rating, eight have issued a Hold rating and three have assigned a Sell rating to the company’s stock. According to MarketBeat, Icon presently has an average rating of “Hold” and a consensus price target of $153.20.

Icon Stock Down 1.7%

Shares of NASDAQ:ICLR traded down $2.34 during trading on Friday, reaching $134.47. 218,518 shares of the stock traded hands, compared to its average volume of 1,586,565. The stock has a market cap of $10.86 billion, a P/E ratio of 21.79, a price-to-earnings-growth ratio of 3.09 and a beta of 1.23. The company has a debt-to-equity ratio of 0.31, a quick ratio of 1.06 and a current ratio of 1.06. The stock has a 50-day moving average of $112.28 and a two-hundred day moving average of $141.50. Icon has a 52-week low of $66.57 and a 52-week high of $211.00.

Icon (NASDAQ:ICLR) last released its quarterly earnings data on Wednesday, May 27th. The medical research company reported $2.52 earnings per share (EPS) for the quarter, missing the consensus estimate of $2.95 by ($0.43). Icon had a net margin of 7.40% and a return on equity of 10.58%. The business had revenue of $2.11 billion during the quarter, compared to the consensus estimate of $1.98 billion. During the same period last year, the company posted $3.43 earnings per share. The business’s revenue was up 2.5% compared to the same quarter last year. Icon has set its FY 2026 guidance at 10.000-11.000 EPS. As a group, sell-side analysts expect that Icon will post 11.53 earnings per share for the current fiscal year.

Institutional Trading of Icon

Several large investors have recently added to or reduced their stakes in the business. Arkadios Wealth Advisors increased its holdings in Icon by 87.6% during the first quarter. Arkadios Wealth Advisors now owns 29,843 shares of the medical research company’s stock valued at $3,302,000 after buying an additional 13,939 shares during the last quarter. Amundi increased its stake in shares of Icon by 88.6% in the 1st quarter. Amundi now owns 33,583 shares of the medical research company’s stock worth $3,716,000 after purchasing an additional 15,773 shares in the last quarter. Royal Bank of Canada raised its holdings in Icon by 68.0% in the 1st quarter. Royal Bank of Canada now owns 153,728 shares of the medical research company’s stock worth $17,011,000 after purchasing an additional 62,225 shares during the period. Eagle Health Investments LP lifted its position in Icon by 45.1% during the first quarter. Eagle Health Investments LP now owns 358,500 shares of the medical research company’s stock valued at $39,672,000 after purchasing an additional 111,410 shares in the last quarter. Finally, Empowered Funds LLC lifted its position in Icon by 21.7% during the first quarter. Empowered Funds LLC now owns 2,609 shares of the medical research company’s stock valued at $289,000 after purchasing an additional 466 shares in the last quarter. 95.61% of the stock is currently owned by institutional investors.

About Icon

Icon plc (NASDAQ: ICLR) is a global provider of outsourced drug development and clinical research services to the pharmaceutical, biotechnology and medical device industries. The company partners with clients at all stages of the product life cycle, offering expertise in protocol design, trial execution and regulatory compliance across a broad range of therapeutic areas.

Icon’s service portfolio encompasses clinical trial management, data management and biostatistics, medical imaging, pharmacovigilance and safety monitoring, laboratory sciences and specialized analytical solutions.